知镜 Cognispect · 医学文献与研究工作台

Hypertension and Blood Pressure Dysregulation in Cancer Survivors: Mechanisms, Management, and Future Directions.

Daniel L, Hundley WG.
Current hypertension reports · 2026-11-10 · PMID 43007571

文献摘要

Purpose of review This review examines the epidemiology, mechanisms, and management of hypertension in patients with cancer, emphasizing treatment-related hypertension, autonomic dysfunction, blood pressure lability, and evolving blood pressure targets in cardio-oncology. Recent findings Among cancer survivors both during and after their cancer treatment, hypertension is highly prevalent and is associated with increased cardiovascular morbidity and mortality. Vascular endothelial growth factor (VEGF) inhibitors are one of the most common causes of cancer treatment-induced hypertension, although other cancer treatments also contribute. Emerging evidence highlights the coexistence of orthostatic hypotension and hypertension, likely related to autonomic dysfunction, arterial stiffening, baroreflex impairment, and endothelial dysfunction related to cancer and its treatment. Medical management, intensive blood pressure control, and cardio-oncology rehabilitation may improve blood pressure control while mitigating adverse outcomes. Current hypertension management in cancer survivors largely follows general population guidelines despite the unique pathophysiology of cancer and its therapies. Future research should establish cancer-specific blood pressure targets, optimize antihypertensive strategies, and further investigate management of blood pressure lability, autonomic dysfunction, and cardio-oncology rehabilitation.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。